Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

• ClinicalTrials.gov Identifier: NCT02315586
• Recruitment Status: Completed
• First Posted: December 12, 2014
• Last Update Posted: January 20, 2023
• Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Study Description

Brief Summary:

Background:

- Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it.

Objectives:

- To discover new pathways that are involved in pulmonary fibrosis. To develop new drugs that may be used to treat pulmonary fibrosis.

Eligibility:

• People at least 18 years old with IPF.
• Healthy volunteers at least 18 years old.

Design:

• Participants will be screened with medical history, questionnaire, and physical exam. They will have blood, lung, and walking tests and chest scans.
• All participants will have 1 study visit, including:
• Medical history and physical exam.
• Questions about their breathing.
• Blood tests.
• Breathing tests.
• Six-minute walk test.
• Pregnancy test.
• Chest x-ray (healthy volunteers) or chest CT scan (people with pulmonary fibrosis ).
• Small area of skin may be removed.
• Genetic tests of blood and skin samples. Participants will probably not be informed of any findings. Samples may be used to make stem cells for use in research. Participants may be contacted in the future to give consent for this research.
• Some participants will have repeat visits over many years, repeating many of the study tests.

Condition or disease
Idiopathic Pulmonary Fibrosis

Detailed Description:

Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective treatments for patients with IPF. Levels of apolipoprotein A-I (apoA-I) have been found to be reduced in the lungs of patients with IPF, while administration of human apoA-I has been shown to reduce bleomycin-induced collagen deposition in a murine model. Here, we would like to assess whether apoA-I pathways modify lung cell biology in patients with IPF. This is a specimen procurement, clinical phenotyping and genotyping protocol that will assess whether holo-apoA-I and apolipoprotein A-I mimetic peptides, can attenuate key pathogenic manifestations of IPF, such as proliferation and extracellular matrix generation by pulmonary fibroblasts, which may serve as evidence to support future human clinical trials of apoA-I for the treatment of IPF. Furthermore, the identification of new apoA-I responsive genes and pathways that mediate fibroblast proliferation in IPF may provide insights into disease pathogenesis and identify new therapeutic targets. Lastly, if induced pluripotent stem (iPS) cells can be successfully shown to model responsiveness of lung cells to apoA-I therapy, then this approach may be expanded with the goal of providing a personalized medicine analysis that could in the future guide selection of the most effective therapy for individual patients.

Study Design

• Study Type: Observational
• Actual Enrollment: 63 participants
• Observational Model: Case-Control
• Time Perspective: Cross-Sectional
• Official Title: Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
• Actual Study Start Date: January 28, 2015
• Actual Primary Completion Date: February 23, 2022
• Actual Study Completion Date: February 23, 2022

Groups and Cohorts

Group/Cohort
1; Participants will be enrolled at the NIH Clinical Center.
2; IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program

Outcome Measures

Primary Outcome Measures :

1. Specimen procurement, clinical phenotyping and genotyping that will assess whether holo-apoA-I and apolipoprotein A-I mimetic peptides, can attenuate key pathogenic manifestations of IPF [ Time Frame: 5 years ]
   Therefore, we request participation of a maximum of 500 subjects (250 IPF patients and 250 non-IPF subjects) to ensure that we have a sufficient number of samples to achieve the goals of the study.

Secondary Outcome Measures :

1. The effects of stimulating cultures of primary pulmonary fibroblasts from IPF patients and subjects without IPF with apolipoprotein A-I will also be compared to the effects seen following stimulation with apolipoprotein E [ Time Frame: 5 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Participants will be enrolled at the NIH Clinical Center. IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program and study procedures will be performed in the outpatient unit/day hospital at the NIH Clinical Center.@@@

Criteria

• INCLUSION CRITERIA:

Patient:

Males and females over the age of 18 with a diagnosis of IPF.

EXCLUSION CRITERIA:

Patient:

Female subjects who are pregnant or lactating

INCLUSION CRITERIA:

Normal Volunteer:

Males and females over the age of 18 without IPF.

EXCLUSION CRITERIA:

Normal Volunteer:

Female subjects who are pregnant or lactating

Contacts and Locations

Locations

United States, Maryland

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Stewart J Levine, M.D.; National Heart, Lung, and Blood Institute (NHLBI)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page 

• Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
• ClinicalTrials.gov Identifier: NCT02315586
• Other Study ID Numbers: 150017; 15-H-0017
• First Posted: December 12, 2014
• Last Update Posted: January 20, 2023
• Last Verified: January 18, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):

Idiopathic Pulmonary Fibrosis; Apoliprotein A-1; Natural History

Additional relevant MeSH terms:

Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis; Fibrosis; Pathologic Processes; Lung Diseases; Respiratory Tract Diseases